Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Journal of Gastrointestinal Oncology|September 16, 2024
Response to hepatic arterial infusion chemotherapy combined with camrelizumab and targeted therapy in advanced primary hepatic neuroendocrine carcinoma: a case report and literature reviewXianmao Shi, Ze Su, Zhiyin Liang, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 5, 2017
Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution ExperienceChenwi M Ambe, Phuong Nguyen, Barbara A Centeno, et al.
The Oncologist|June 14, 2019
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real WorldJonathan Strosberg, Vijay N Joish, Susan Giacalone, et al.
Pancreas|February 9, 2021
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 StudiesDavid L Chan, James C Yao, Carlo Carnaghi, et al.
Chest|February 16, 2020
Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell HyperplasiaTaymeyah Al-Toubah, Jonathan Strosberg, Thorvardur R Halfdanarson, et al.
Oncology|December 7, 2023
RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and NivolumabRuoyu Miao, Dae Won Kim, James Yu, et al.
Cancers|February 10, 2024
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal CancerDae Won Kim, Young-Chul Kim, Bence P Kovari, et al.
Cancer|April 15, 2021
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trialsNicola Fazio, Carlo Carnaghi, Roberto Buzzoni, et al.
Cancers|June 24, 2022
Perioperative Carcinoid Crisis: A Systematic Review and Meta-AnalysisAileen Xu, Pilar Suz, Tea Reljic, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2023
Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysisSatya Das, Sharon Phillips, Cody L Lee, et al.
Pageof 12